Latest News

May 26, 2020
To aid in the treatment of cardiovascular disease (CVD), women are more likely to use preventive measures while men are typically treated with surgical interventions. Women are also less likely to die from CVD than men, according to recent study results published in The Lancet.
May 26, 2020
President Trump announced the plan today at the White House, accompanied by insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi, as well as AHIP and major health plans.
May 26, 2020
There has been an uneven distribution of bailout funds among economically disparate hospitals under the CARES Act; people are medicating as a result of increasing stress from the coronavirus disease 2019 pandemic; the World Health Organization stops trials of hydroxychloroquine.
May 26, 2020
Migraineurs’ brains experience disrupted functional connectivity (FC) between subregions in the sensorimotor areas and cortex, according to a study published in The Journal of Headache and Pain.
May 25, 2020
In the first report of its kind, researchers examined the combined effect of liraglutide and propranolol on the hearts of patients with both type 2 diabetes and cirrhosis.
May 25, 2020
Refractive evaluation should be considered for working-age adults with eye disease and reduced visual acuity, especially if they are new to seeking care for low vision, according to a study published in JAMA Ophthalmology.
 
May 24, 2020
Cognitive behavioral therapy for insomnia was found to reduce severity of obstructive sleep apnea (OSA) by 15% in patients with comorbid insomnia and OSA, according to study findings.
May 24, 2020
Trastuzumab deruxtecan, an antibody–drug conjugate (ADC) marketed as Enhertu, has been granted Orphan Drug Designation (ODD) for the treatment of gastric cancer, including gastroesophageal junction cancer.
 
May 23, 2020
A majority of women younger than 45 years faced employment and insurance coverage difficulties following treatment for early stage breast cancer, with 35% fearing loss of health insurance coverage if they left their current job during treatment—despite wanting to continue working.
 
May 23, 2020
Ruxolitinib was found to be more cost-effective than the best available therapy (BAT) when the willingness-to-pay threshold for payers was at $150,000 and applied to patients with hydroxyurea resistant/intolerant polycythemia vera (PV) without splenomegaly, according to a new study.
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.